Fuji Submits NDI to FDA

Fuji Submits NDI to FDA

MOUNT LAUREL, N.J.Fuji HealthScience Inc., a subsidiary of Toyama, Japan-based Fuji Chemical Industry Co.Ltd., submitted a New Dietary Ingredient (NDI) notification to the U.S. Food andDrug Administration (FDA) for AstaREAL® astaxanthin produced at its facility inGustavsberg, Sweden. According to Fuji Health Science, it has been marketing itsastaxanthin under its original NDI for AstaREAL produced in Hawaii; the new NDIwas submitted to permit greater capacity and product flexibility.

This new NDI gives us the ability to supply the market withthe very highest quality astaxanthin at competitive pricing, said CharlesDePrince, president of Fuji Health Science (www.fcihealthscience.com).